CNS-Derived Blood Exosomes as a Promising Source of Biomarkers: Opportunities and Challenges

• Published in: Frontiers in molecular neuroscience Vol. 13; p. 38
• Main Authors: Hornung, Simon, Dutta, Suman, Bitan, Gal
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 19.03.2020
• Subjects: Alzheimer' disease; biomarker; exosome; extracellular vesicle (EV); neurodegenerative diseases; Neuroscience; Parkinson's and related diseases; neurodegenerative diseases; extracellular vesicle (EV); Parkinson's and related diseases; ALS; Alzheimer' disease; biomarker; exosome
• ISSN: 1662-5099; 1662-5099
• DOI: 10.3389/fnmol.2020.00038

Eukaryotic cells release different types of extracellular vesicles (EVs) including exosomes, ectosomes, and microvesicles. Exosomes are nanovesicles, 30-200 nm in diameter, that carry cell- and cell-state-specific cargo of proteins, lipids, and nucleic acids, including mRNA and miRNA. Recent studies have shown that central nervous system (CNS)-derived exosomes may carry amyloidogenic proteins and facilitate their cell-to-cell transfer, thus playing a critical role in the progression of neurodegenerative diseases, such as tauopathies and synucleinopathies. CNS-derived exosomes also have been shown to cross the blood-brain-barrier into the bloodstream and therefore have drawn substantial attention as a source of biomarkers for various neurodegenerative diseases as they can be isolated via a minimally invasive blood draw and report on the biochemical status of the CNS. However, although isolating specific brain-cell-derived exosomes from the blood is theoretically simple and the approach has great promise, practical details are of crucial importance and may compromise the reproducibility and utility of this approach, especially when different laboratories use different protocols. In this review we discuss the role of exosomes in neurodegenerative diseases, the usefulness of CNS-derived blood exosomes as a source of biomarkers for these diseases, and practical challenges associated with the methodology of CNS-derived blood exosomes and subsequent biomarker analysis.